# Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma

> **NCT00253578** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 40 (estimated)

## Conditions studied

- Refractory Multiple Myeloma

## Interventions

- **DRUG:** sorafenib tosylate
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00253578
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2007-11
- **Final completion:** —
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2013-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00253578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00253578, "Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-08-19 from https://api.ai-analytics.org/clinical/NCT00253578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*